Supplementary Materials and Methods from Recharacterization of the Tumor Suppressive Mechanism of RSL3 Identifies the Selenoproteome as a Druggable Pathway in Colorectal Cancer

Key Points

RSL3's role in colorectal cancer is linked to tumor suppressive mechanisms.
New synthetic procedures for biotinylated analogs are outlined with specific reagents and yields.
The study identifies the selenoproteome as a potential druggable pathway in cancer treatment.
Understanding the selenoproteome may lead to novel approaches for targeting colorectal cancer.

Supplementary methods detail synthetic procedures for biotinylated analogs, highlighting selenoproteome as a target in colorectal cancer.

No abstract yet. The journal hasn't published one we can show.

No takes yet. Share an insight, caveat, or question.

DeAngelo et al. (2025) studied this question.

View at Publisher

Ask AI

Bookmark

Share